The Food and Drug Administration Safety and Innovation Act, directed the US Food and Drug Administration (FDA) to report on the extent to which demographic subgroups participate in clinical trials in marketing applications for drugs, biologics, and devices. Regina Ballinger of Thomson Reuters discusses the Action Plan which follows the publication of this report.